This is a standard annual shareholder meeting with no material financial impact. Shareholders should vote on the proposals, but no significant changes to company strategy or operations are expected.
Price Chart
Executive Summary
Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders. The proxy statement outlines proposals for the election of three directors, ratification of the independent auditor, and advisory votes on executive compensation. This is a routine corporate governance filing.
Key Facts
- Neumora Therapeutics, Inc. is holding its 2026 annual meeting of stockholders.
- Proposals include the election of three Class III directors: Paul Berns, Matthew Fust, and David Piacquad.
- Shareholders are asked to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.
- Advisory votes on the compensation of named executive officers and the frequency of future advisory votes are also on the agenda.
Financial Impact
Routine corporate governance matters; no direct financial impact.
Risk Factors
- Failure to ratify the auditor could lead to delays in financial reporting, but this is highly unlikely.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-161519 |
| Document: 0001193125-26-161519-index-headers.html | 0001193125-26-161519 |
| Document: 0001193125-26-161519-index.html | 0001193125-26-161519 |
| Document: 0001193125-26-161519.txt | 0001193125-26-161519 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | 144 | $1.63 $0.6918 | ▲ +57.56% | ▲ +57.03% | $0.4999 (+69.33%) |
Aug 17, 2026 6w ago | 144 | $1.64 $0.7732 | ▲ +52.85% | ▲ +51.54% | $0.4999 (+69.52%) |
Aug 14, 2026 7w ago | 8-K | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Aug 14, 2026 7w ago | Press Release | $1.60 $0.9994 | ▼ −37.54% | ▼ −35.55% | $0.4999 (−68.76%) |
Jul 27, 2026 9w ago | 8-K | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jul 27, 2026 9w ago | Press Release | $1.66 $1.53 | ▼ −8.13% | ▼ −11.43% | $0.4999 (−69.89%) |
Jun 15, 2026 15w ago | 8-K | $0.9145 $1.60 | ▼ −74.96% | ▼ −75.71% | $0.4999 (+45.34%) |
Apr 17, 2026 24w ago | DEFA14A | $2.19 $1.77 | ▼ −19.18% | ▼ −23.38% | $0.4999 (−77.17%) |
Mar 30, 2026 26w ago | Press Release | $1.93 $2.25 | ▲ +16.58% | ▲ +3.98% | $0.4999 (−74.10%) |
Mar 16, 2026 28w ago | Press Release | $2.87 $2.03 | ▼ −29.27% | ▼ −33.05% | $0.4999 (−82.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access